reported that NEK1 is highly expressed in RCC cells and exerts antiapoptotic effects through VDAC1 phosphorylation, resulting in decreased sensitivity to DNA damage treatment.[69] Due to the critical role of NEK1 in DNA damage repair, NEK1‐specific inhibitors may serve as potential antitumor drug targets.[70] In this study, we demonstrated that HDAC8 repression increased the expression of NEK1, which phosphorylates ETS1 at the T241 site and blocks the acetylation of ETS1 at the T245 site to promote ETS1 binding with HIF2A. The gene discussed is EPAS1; the disease is renal cell carcinoma.